,Hong Kong

SciClone profit up 4.3% to RMB622.7m in H1 2021

Its revenue rose 14.7% to RMB1.3b in the same period. 

Hong Kong Exchange-listed SciClone Pharmaceuticals (Holdings) Limited posted a 4.3% increase in net profit attributable to shareholders to RMB622.7m in the first half of 2021 from RMB597b, in the same period last year.

Its revenue rose 14.7% in the first six months of the year to RMB1.3b, from RMB1.16b in the same period last year, it said in a disclosure to the bourse.

SciClone also posted a 9.9% increase in revenue from sales of its proprietary product Zadaxin to RMB1.1b during the period despite the high base of sales for the prevention and clinical treatment of COVID-19 in China in the same first half of 2020.

The Pharmaceuticals company also completed the transfer of import drug license for Zometa and became its marketing authorization holder in China in January, with revenue from the provinces wherein the registered distributor had been converted from Novartis to the company was RMB54.m.

“Leveraging our integrated platform, we have established a balanced product portfolio focusing on high potential therapeutic areas, led by marketed products with strong cash generation ability through effective lifecycle management, and supported by an innovative pipeline with first-in-class/best-in-class potential to drive sustainable long-term growth,” it said.

During the first half, among the development milestones reached by the company include the pilot launch of DANYELZA® (naxitamab) “for the treatment of patients with relapsed/refractory high-risk neuroblastoma in Hainan Bo’Ao Lecheng International Medical Tourism Pilot Zone in June.”

The National Medical Products Administration (NMPA) of China accepted its Biologics License Application for the said treatment in July, with the first prescription issued in early August.

It also submitted the investigation of new drugs application of RRx-001 Multi-Regional Clinical Trials Phase III study in the “third line and beyond small cell lung cancer in China to the NMPA which was approved in July, amongst others.

Get Healthcare Asia Magazine in your inbox
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Treatment options for NSCLC patients with EGFR mutation can now be accessed.
The report surveyed 500 senior-level hospital leaders.
Furthermore, Washington's vaccine donations are now at six million.
Meanwhile, 100% of public hospitals have installed hospital information systems as of July 2019.
It will guide the better application of Internet medical care in the prevention and control of AIDS.
The procedure is a breakthrough in treating leaking heart valves.
The hospital reportedly violated COVID guidelines and charged a patient excessively.
It also announces the addition of nearly 7,000 new beds, which will all be available in mid-2022.
Operation Surge Capacity helped reduce the usage from 130% to 80%.
Robotics are innovating the Singaporean healthcare industry through precision and power.
The machine aims to improve the diagnosis and treatment of pediatric cardiac conditions in the country.
This is following a net loss of $98m in the same period last year.
Fitch Solutions expects the government to ramp up its healthcare expenditure in the coming years.